ISDA: 7MBO

7MBO image

Deposition Date 2021-04-01

Release Date 2021-09-15

Last Version Date 2024-11-20

Entry Detail

PDB ID:

7MBO

Keywords:

HYDROLASE/HYDROLASE INHIBITOR

Title:

FACTOR XIA (PICHIA PASTORIS; C500S [C122S]) IN COMPLEX WITH THE INHIBITOR Milvexian (BMS-986177), IUPAC NAME:(6R,10S)-10-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6- oxopyrimidin-1(6H)-yl}-1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-15,11- (metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Komagataella pastoris

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

0.92 Å

R-Value Free:

0.16

R-Value Work:

0.16

R-Value Observed:

0.16

Space Group:

P 21 21 21

7MBO validation report

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Coagulation factor XIa light chain
Gene (Uniprot):F11
Mutagens:C500S
Chain IDs:A
Chain Length:238
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P03951 Pfam ID:PF00089 EC:3.4.21.27

Ligand Molecules

NAG

YXG

Primary Citation

Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.

Dilger, A.K, Pabbisetty, K.B, Corte, J.R, De Lucca, I, Fang, T, Yang, W, Pinto, D.J.P, Wang, Y, Zhu, Y, Mathur, A, Li, J, Hou, X, Smith, D, Sun, D, Zhang, H, Krishnananthan, S, Wu, D.R, Myers Jr, J.E, Sheriff, S, Rossi, K.A, Chacko, S, Zheng, J.J, Galella, M.A, Ziemba, T, Dierks, E.A, Bozarth, J.M, Wu, Y, Crain, E, Wong, P.C, Luettgen, J.M, Wexler, R.R, Ewing, W.R, Quan, M.L, Wong, P.C, Wang, C, Woerner, F, Smallheer, J.M, Barbera, F.A, Bozarth, J.M, Brown, R.L, Harpel, M.R, Luettgen, J.M, Morin, P.E, Peterson, T, Ramamurthy, V, Rendina, A.R, Rossi, K.A, Watson, C.A, Wei, A, Zhang, G, Seiffert, D, Wexler, R.R, Hangeland, J.J, Friends, T.J, Rossi, K.A, Smallheer, J.M, Wang, C, Sun, Z, Corte, J.R, Fang, T, Wong, P.C, Rendina, A.R, Barbera, F.A, Bozarth, J.M, Luettgen, J.M, Watson, C.A, Zhang, G, Wei, A, Ramamurthy, V, Morin, P.E, Bisacchi, G.S, Subramaniam, S, Arunachalam, P, Mathur, A, Seiffert, D.A, Wexler, R.R, Quan, M.L, Corte, J.R, Fang, T, Hangeland, J.J, Friends, T.J, Rendina, A.R, Luettgen, J.M, Bozarth, J.M, Barbera, F.A, Rossi, K.A, Wei, A, Ramamurthy, V, Morin, P.E, Seiffert, D.A, Wexler, R.R, Quan, M.L, Pinto, D.J, Smallheer, J.M, Corte, J.R, Austin, E.J, Wang, C, Fang, T, Smith II, L.M, Rossi, K.A, Rendina, A.R, Bozarth, J.M, Zhang, G, Wei, A, Ramamurthy, V, Sheriff, S, Myers Jr, J.E, Morin, P.E, Luettgen, J.M, Seiffert, D.A, Quan, M.L, Wexler, R.R, Hu, Z, Wong, P.C, Gilligan, P.J, Han, W, Pabbisetty, K.B, Bozarth, J.M, Crain, E.J, Harper, T, Luettgen, J.M, Myers Jr, J.E, Ramamurthy, V, Rossi, K.A, Sheriff, S, Watson, C.A, Wei, A, Zheng, J.J, Seiffert, D.A, Wexler, R.R, Quan, M.L, Smith II, L.M, Orwat, M.J, Hu, Z, Han, W, Wang, C, Rossi, K.A, Gilligan, P.J, Pabbisetty, K.B, Osuna, H, Corte, J.R, Rendina, A.R, Luettgen, J.M, Wong, P.C, Narayanan, R, Harper, T.W, Bozarth, J.M, Crain, E.J, Wei, A, Ramamurthy, V, Morin, P.E, Xin, B, Zheng, J, Seiffert, D.A, Quan, M.L, Lam, P.Y.S, Wexler, R.R, Pinto, D.J.P, Corte, J.R, Fang, T, Pinto, D.J, Orwat, M.J, Rendina, A.R, Luettgen, J.M, Rossi, K.A, Wei, A, Ramamurthy, V, Myers Jr, J.E, Sheriff, S, Narayanan, R, Harper, T.W, Zheng, J.J, Li, Y.X, Seiffert, D.A, Wexler, R.R, Quan, M.L, Corte, J.R, Fang, T, Osuna, H, Pinto, D.J, Rossi, K.A, Myers Jr, J.E, Sheriff, S, Lou, Z, Zheng, J.J, Harper, T.W, Bozarth, J.M, Wu, Y, Luettgen, J.M, Seiffert, D.A, Decicco, C.P, Wexler, R.R, Quan, M.L, Corte, J.R, Yang, W, Fang, T, Wang, Y, Osuna, H, Lai, A, Ewing, W.R, Rossi, K.A, Myers Jr, J.E, Sheriff, S, Lou, Z, Zheng, J.J, Harper, T.W, Bozarth, J.M, Wu, Y, Luettgen, J.M, Seiffert, D.A, Quan, M.L, Wexler, R.R, Lam, P.Y.S, Wang, C, Corte, J.R, Rossi, K.A, Bozarth, J.M, Wu, Y, Sheriff, S, Myers Jr, J.E, Luettgen, J.M, Seiffert, D.A, Wexler, R.R, Quan, M.L, Pinto, D.J.P, Orwat, M.J, Smith II, L.M, Quan, M.L, Lam, P.Y.S, Rossi, K.A, Apedo, A, Bozarth, J.M, Wu, Y, Zheng, J.J, Xin, B, Toussaint, N, Stetsko, P, Gudmundsson, O, Maxwell, B, Crain, E.J, Wong, P.C, Lou, Z, Harper, T.W, Chacko, S.A, Myers Jr, J.E, Sheriff, S, Zhang, H, Hou, X, Mathur, A, Seiffert, D.A, Wexler, R.R, Luettgen, J.M, Ewing, W.R, Clark, C.G, Rossi, K.A, Corte, J.R, Fang, T, Smallheer, J.M, De Lucca, I, Nirschl, D.S, Orwat, M.J, Pinto, D.J.P, Hu, Z, Wang, Y, Yang, W, Jeon, Y, Ewing, W.R, Myers Jr, J.E, Sheriff, S, Lou, Z, Bozarth, J.M, Wu, Y, Rendina, A, Harper, T, Zheng, J, Xin, B, Xiang, Q, Leuttgen, J.M, Seiffert, D.A, Wexler, R.R, Lam, P.Y.S, Corte, J.R, Pinto, D.J.P, Fang, T, Osuna, H, Yang, W, Wang, Y, Lai, A, Clark, C.G, Sun, J.-H, Rampulla, R, Mathur, A, Kaspady, M, Neithnadka, P.R, Li, Y.-X.C, Rossi, K.A, Myers Jr, J.E, Sheriff, S, Lou, Z, Harper, T.W, Huang, C, Zheng, J.J, Bozarth, J.M, Wu, Y, Wong, P.C, Crain, E.J, Seiffert, D.A, Luettgen, J.M, Lam, P.Y, Wexler, R.R, Ewing, W.R, Fang, T, Corte, J.R, Gilligan, P.J, Jeon, Y, Osuna, H, Rossi, K.A, Myers Jr, J.E, Sheriff, S, Lou, Z, Zheng, J.J, Harper, T.W, Bozarth, J.M, Wu, Y, Luettgen, J.M, Seiffert, D.A, Wexler, R.R, Lam, P.Y.S, Yang, W, Wang, Y, Lai, A, Clark, C.G, Corte, J.R, Fang, T, Gilligan, P.J, Jeon, Y, Pabbisetty, K.B, Rampulla, R.A, Mathur, A, Kaspady, M, Neithnadka, P.R, Arumugam, A, Raju, S, Rossi, K.A, Myers Jr, J.E, Sheriff, S, Lou, Z, Zheng, J.J, Chacko, S.A, Huang, C.S, Bozarth, J.M, Wu, Y, Crain, E.J, Wong, P.C, Seiffert, D.A, Luettgen, J.M, Lam, P.Y.S, Wexler, R.R, Ewing, W.R.Show

J.Med.Chem. 65 1770 1785 (2022)

PMID: 34494428 DOI: 10.1021/acs.jmedchem.1c00613

Abstact

Factor XIa (FXIa) is an enzyme in the coagulation cascade thought to amplify thrombin generation but has a limited role in hemostasis. From preclinical models and human genetics, an inhibitor of FXIa has the potential to be an antithrombotic agent with superior efficacy and safety. Reversible and irreversible inhibitors of FXIa have demonstrated excellent antithrombotic efficacy without increased bleeding time in animal models (Weitz, J. I., Chan, N. C. Arterioscler. Thromb. Vasc. Biol. 2019, 39 (1), 7-12). Herein, we report the discovery of a novel series of macrocyclic FXIa inhibitors containing a pyrazole P2' moiety. Optimization of the series for (pharmacokinetic) PK properties, free fraction, and solubility resulted in the identification of milvexian (BMS-986177/JNJ-70033093, 17, FXIa Ki = 0.11 nM) as a clinical candidate for the prevention and treatment of thromboembolic disorders, suitable for oral administration.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

7MBO